“Immunogenicity of Guselkumab (GUS) Among Psoriasis Patients in VOYAGE (VOY) 1&2 Studies”. SKIN The Journal of Cutaneous Medicine, vol. 6, no. 2, Mar. 2022, p. s11, https://doi.org/10.25251/skin.6.supp.11.